EVERY Company Advances with New Patent for Protein Innovation
EVERY Company Secures Key Patent for Ovalbumin
San Francisco-based food technology innovator, The EVERY Company, has achieved a significant milestone by securing its latest foundational patent, US 12/096,784. This patent showcases a groundbreaking development in the production of egg proteins through precision fermentation, thereby enhancing EVERY’s intellectual property and showcasing its leadership in food tech.
What is Covered by the Patent?
The newly awarded patent encompasses any food ingredient composition that integrates recombinant ovalbumin — the primary protein found in egg whites — along with at least one other consumable component. Ovalbumin accounts for more than 54% of egg white protein, mainly contributing to foaming, binding, gelling, and enriching the nutritional profile in various culinary applications.
Innovative Aspects of the Patent
This pivotal patent incorporates a wide range of innovations, such as:
- Enhanced performance variants of wild-type ovalbumin achieved through various modifications.
- Ovalbumin derived from several avian species and production techniques that utilize different yeast and fungal systems, including Pichia, Trichoderma, Saccharomyces, and Aspergillus.
Diverse Applications and Formats
Moreover, the scope of this patent includes numerous product formats, which span baked goods, binding agents for meat and meat substitutes, ready-to-eat egg dishes, whipped cream, ice cream, meringues, and beyond. The patent also encompasses functional applications related to hardness, cohesiveness, springiness, chewiness, and foam stability, available in both liquid and powdered forms.
Milestone for EVERY's Product Range
“This patent marks a tremendous milestone for EVERY, given the versatility of ovalbumin as a functional powerhouse,” remarked Arturo Elizondo, Co-Founder and CEO of EVERY. He emphasized that ovalbumin is the core ingredient that powers EVERY’s egg white alternatives used in a variety of complex applications. Notably, it was also the unique protein featured in EVERY Egg, showcased at the prestigious 3-Michelin star restaurant Eleven Madison Park.
The applications of EVERY Egg stretch from pisco sours to coddled egg vinaigrettes to delicate chawanmushi and the classic omelet. This exciting news follows closely behind EVERY’s international partnerships with several well-known companies, as the organization gears up for broad market entry.
Looking Ahead for EVERY
“This patent is the result of nearly a decade of dedicated research, further solidifying our status as a pioneer in the industry,” stated Elizondo. “Exciting endeavors lie ahead as we aim to build upon this success and propel our intellectual property forward.”
About The EVERY Company
The EVERY Company is committed to reshaping the future of food systems by providing accessible and secure protein ingredients produced through precision fermentation techniques. Based in San Francisco, EVERY focuses on delivering nature-equivalent proteins that serve a multitude of food and beverage companies.
Among its extensive range of innovative and FDA-approved products is EVERY EggWhite™, designed to replace the functional aspects of traditional eggs and egg whites across various applications. Additionally, EVERY Protein™ is a highly soluble protein that enhances diverse food and beverage offerings such as coffees, juices, sodas, syrups, and baked goods.
Frequently Asked Questions
What is ovalbumin and why is it important?
Ovalbumin is the main protein in egg whites, making up over 54% of the protein in eggs. It is crucial for many food applications due to its foaming and binding properties.
What innovations does the new patent cover?
The patent covers variations of ovalbumin and novel methods of production using yeast and fungi, enhancing its functionality in various foods.
How does EVERY's patent benefit the food industry?
The patent allows food manufacturers to create new products with enhanced nutritional and functional properties, promoting innovation in food technology.
What products does EVERY offer?
EVERY offers several innovative protein products including EVERY EggWhite™ and EVERY Protein™, designed to replace traditional egg ingredients in various applications.
What are EVERY's future plans?
EVERY aims to expand its market reach and continue innovating its product line while further developing its intellectual property portfolio.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Oxford Lane Capital's OXLCP Stock Reaches New Heights
- Nathan's Famous Inc. Surpasses 52-Week High With Robust Growth
- Algonquin Power Stock Surges to New Heights with 52-Week Milestone
- Siebert Financial Reaches New Heights with $2.54 Stock Price
- United Community Banks, Inc. Sets Earnings Release Date for Q3 2024
- Arizona Sonoran Copper Company Pursues C$30 Million Financing
- Historic Groundbreaking Ceremony for Skilled Trades Center
- Legal Action Filed for Domino's Pizza, Inc. (DPZ) Shareholders
- Kevin Crigger Steps Up as TRREB's New Associate CEO
- Legal Action Launched for Shareholders of Walgreens (WBA)
Recent Articles
- Koryx Copper Enhances Leadership to Propel Haib Copper Project
- Silexion Therapeutics Unveils Promising Phase 2 LODER Data
- Zevra Therapeutics Shares Promising Data on KP1077 for IH
- DocGo Recognized as Finalist for Compliance Excellence Awards
- HOOKIPA Pharma Showcases Promising HB-700 Data Advances
- Duane Richins Joins Real Brokerage to Transform Real Estate Sales
- Tesla's Resurgence: What Drives Its Stock Performance Today?
- Empowering Rural Workforce: New Strategies for Success
- Mackenzie Investments Releases Cash Distributions for ETFs
- Avanti Residential and Funnel: A Partnership for Success
- Corero Network Security Reports Impressive H1 2024 Results
- Highway Holdings Announces $0.02 Cash Dividend, Shows Growth
- Camtek Launches Cutting-Edge Eagle G5 System for Growth
- Regula 5006: Setting New Standards in Forensic Technology Design
- Kuber Mortgage Investment Reaches Major Growth Milestone
- Vertu Capital Invests in LumiQ to Enhance Corporate Learning
- MAGRABi and Rivoli Vision Unite to Transform Middle East Eyewear
- Sony's Innovative OLED Microdisplay Sets New Industry Standards
- Hexaware's Innovative CDAaaS Transforms Clinical Data Management
- BTQ Technologies Enhances Quantum-Secure Offerings with Acquisition
- Masdar's Strategic Acquisition of Saeta: A Renewable Energy Boost
- Gates Capital Management Advocates for All-Cash Sale of Vista
- Morgan Stanley Lowers Ratings for European Oil and Gas Stocks
- Evergy Welcomes New Board Members to Strengthen Leadership
- Acurx Pharmaceuticals Advances Ibezapolstat Toward Phase 3 Trials
- CEVA and Edge Impulse: Revolutionizing Edge AI Development
- Palantir Technologies Sees Strong Growth and AI Recognition
- Vishay Intertechnology's Strategic Restructuring For Growth
- Morgan Stanley Boosts Foghorn Therapeutics Stock Price Outlook
- Clearfield's Future Looks Bright with Strategic Insights
- Boeing Faces Extended Delays Post-Strike, Ryanair Confirms
- Draganfly's Commander 3XL to Enhance Military Logistics
- Exploring the Expansive Future of Electrical Insulation Materials
- Exploring the Expanding Market of Second-Hand Luxury Goods
- Railway Sleeper Market on Track for 5.7% CAGR Growth Ahead
- Unlock Passive Income with Brighty App's Crypto Cards
- Repligen's New Training Center Boosts Customer Engagement
- Midland and Wallbridge Initiate Gold Drill Campaign at Casault
- HOOKIPA Pharma Unveils Promising HB-700 Preclinical Results
- BankNewport Enhances Consumer Banking Experience with nCino
- Ocugen's CEO to Discuss Innovative Gene Therapies in NYC
- Kaspi.kz: Enhancing Lives with Innovative Mobile Services
- Jørgen Kjær Jacobsen Steps Down as Chairman of Gabriel Holding
- Recent Share Transactions by Danske Bank Management Insights
- AGF Management and Archer Collaborate for Enhanced Growth
- Castellum, Inc. Secures $4.1 Million Contract with Epic Systems
- Citi Elevates Price Target for ConAgra Ahead of Earnings Release
- MacroGenics Investors Alerted: Deadline to Join Lawsuit Approaches
- TransUnion's Upcoming Q3 2024 Financial Results Announcement
- Warner Bros. Discovery Leverages AI for Cost-Effective Captioning